Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Q1 2018 Earnings Conference Call - Final Transcript

May 10, 2018 • 08:30 am ET


Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Q1 2018 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day, and welcome to today's program. My name is Erica, and I'll be your conference operator.

At this time, I'd like to welcome everyone to Eagle Pharmaceutical's First Quarter 2018 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer period. (Operator Instructions). As a reminder, this conference call is being recorded, May 10, 2018.

It is now my pleasure to turn the floor over to Ilanit Allen, Investor Relations for Eagle Pharmaceuticals. Please go ahead, ma'am.

Ilanit Allen

Thank you, Erica. Welcome to Eagle Pharmaceuticals' first quarter 2018 earnings call. This is Ilanit Allen of In-Site Communications, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's Chief Executive Officer, Scott Tarriff and Chief Financial Officer, Pete Meyers. This morning, the company issued a press release detailing financial results for the three months ended March 31, 2018. This press release and a webcast of this call can be accessed through the Investors section of the Eagle Web site at eagleus.com.

Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance maybe considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to Eagle Pharmaceutical's management as of today and involve risks and uncertainties including those noted in this morning's press release and our filings with the SEC. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. Eagle Pharmaceuticals specifically disclaims any intent or obligation to update these forward-looking statements except as required by law. A telephone replay will be available shortly after completion of this call. You will find the dial-in information in today's press release. The archived webcast will be available for one year on our Web site, eagleus.com.

For the benefit of those who maybe listening to the replay or archived webcast, this call was held and recorded on May 10, 2018. Since then, Eagle may have made announcements related to the topics discussed. So please reference the company's most recent press releases and SEC filings.

And with that, I'll turn the call over to Eagle's CEO, Scott Tarriff.

Scott Tarriff

Good morning, everyone. At Eagle, we have been focused on executing a multipronged strategy to build long-term sustainable value for shareholders and deliver best-in-class products for patients. With our existing portfolio, we have identified opportunities to protect and expand our bendamustine and RYANODEX franchises by advancing solutions at the unmet needs in the marketplace, and which I will discuss in greater detail shortly. And with our pipeline, we have multiple product candidates that offer promising formulations in several attractive markets. In other words, we believe we have a solid business today with multiple opportunities for upside. As you know, currently, we derive the bulk of